HB1583 requires health benefit plans offered, issued, renewed, delivered, or extended in Arkansas to cover medically necessary treatment for acquired brain injury beginning January 1, 2026. The bill defines acquired brain injury broadly to include injuries caused by conditions such as stroke, traumatic brain injury, diminished oxygen, toxins, tumors, infectious disease, metabolic or endocrine disorders, and diseases affecting blood supply to the brain. It also defines a range of covered therapies and services, including cognitive rehabilitation, cognitive communication therapy, community reintegration services, functional rehabilitation therapy, neurocognitive therapy, neurobehavioral therapy, neurofeedback therapy, neuropsychological testing, inpatient and outpatient services, home and community-based treatment, and post-acute residential treatment.
The bill limits how insurers may manage this coverage. It bars lifetime limits and unreasonable annual limits on the number of days or sessions, prohibits higher deductibles, coinsurance, copayments, or out-of-pocket limits than those applied to other benefits, and states that the coverage cannot reduce other benefits available under the plan. For covered services, only a clinical peer reviewer may preauthorize coverage or conduct utilization review, and the Insurance Commissioner must create an expedited appeal process for adverse determinations. The bill also directs the Insurance Commissioner to promulgate implementation rules and asks the Department of Human Services to seek a Medicaid waiver or otherwise add this population to an existing waiver program for home and community-based services.
The bill’s impact is to amend Arkansas insurance law by creating a new subchapter in Title 23 governing coverage for acquired brain injury. It affects health insurers, health maintenance organizations, hospital and medical service corporations, self-insured governmental or church plans, and nonprofit agricultural membership organizations, while excluding certain limited-benefit plans such as dental-only, vision-only, accident-only, and workers’ compensation-related coverage. It also potentially affects Medicaid administration by requiring DHS to pursue additional home and community-based service authority for beneficiaries with acquired brain injury.
The overall sentiment appears strongly supportive. The bill passed the House and Senate overwhelmingly on third reading, with only one no vote in the House and unanimous support in the Senate, suggesting broad bipartisan agreement on expanding access to brain injury treatment. No committee transcript is available, but the voting pattern indicates little organized opposition in the final stages.
The main points of contention likely center on insurance mandates and cost. The bill requires broad coverage for specialized rehabilitation and therapy services, restricts utilization management, and limits cost-sharing differences, which could raise concerns among insurers about premium impact and administrative burden. Another possible issue is the breadth of the definition of acquired brain injury and the range of services included, which may prompt questions about medical necessity standards, provider qualifications, and the scope of covered post-acute and community-based care.
HB1583 creates a new Arkansas insurance subchapter mandating coverage for medically necessary acquired brain injury treatment in most health benefit plans starting January 1, 2026. It expands insurer obligations, limits benefit design and utilization review practices, and requires rulemaking by the Insurance Commissioner. It also directs DHS to seek Medicaid waiver authority or use an existing waiver to support home and community-based services for this population.
The bill appears to have had very favorable legislative support. It passed the House 94-1 and the Senate 34-0 on third reading, indicating broad bipartisan approval and little visible opposition at final passage. The available record does not include committee debate, but the vote totals suggest the measure was viewed positively as a coverage-expansion and patient-access bill.
Likely areas of contention involve the cost and scope of the insurance mandate. Insurers may be concerned about requiring coverage for a wide array of therapies, prohibiting annual or lifetime limits, and restricting utilization review to clinical peer reviewers. Questions may also arise over how broadly acquired brain injury is defined, how medical necessity will be determined, and whether the Medicaid waiver request could create additional state obligations or administrative complexity.